Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy

Molecular Psychiatry

Volumn 7, Issue 5, 2002, Pages 468-473

  Capuron, L ^a,c   Ravaud, A ^b   Neveu, P J ^a   Miller, A H ^c   Maes, M ^d   Dantzer, R ^a  

^a INSTITUT FRANÇOIS MAGENDIE   (France)

^b INSTITUT BERGONIÉ   (France)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Amino acids; Cytokine; Depressive symptoms; Immunotherapy; Tryptophan

Indexed keywords

ALPHA INTERFERON; AMINO ACID; CYTOKINE; INTERLEUKIN 2; ISOLEUCINE; LEUCINE; PHENYLALANINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; TRYPTOPHAN; TYROSINE; VALINE; BIOLOGICAL MARKER;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID TRANSPORT; ARTICLE; BLOOD BRAIN BARRIER; CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MELANOMA; PATHOGENESIS; PRIORITY JOURNAL; RATING SCALE; BLOOD; MIDDLE AGED; NEOPLASM; PSYCHOLOGICAL ASPECT; REGRESSION ANALYSIS; TIME;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; CYTOKINES; DEPRESSIVE DISORDER; FEMALE; HUMAN; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MIDDLE AGE; NEOPLASMS; REGRESSION ANALYSIS; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TRYPTOPHAN; HUMANS; MIDDLE AGED;

EID: 0035985472     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000995     Document Type: Article

References (47)

1. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression
2. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features
3. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells
4. Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-alpha
5. Depression from interferon therapy in patients with hepatitis C
6. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy
7. Cytokines and brain function: Relevance to interferon-alpha-induced mood and cognitive changes
8. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
9. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
10. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state
11. The serotonin hypothesis of major depression
12. Use of neurotransmitter precursors for treatment of depression
13. Tryptophan transport to the brain: New findings and older ones reconsidered
14. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor
15. Plasma tryptophan and five other amino acids in depressed and normal subjects
16. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress
17. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment
18. Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypothalamicpituitary-adrenocortical axis activity, and body temperature
19. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain
20. Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin-2
21. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS
22. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression
23. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis
24. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
25. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
26. A new depression scale designed to be sensitive to change
27. Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography
28. Lower serum L-tryptophan availability in depression as a marker of a more generalized disorder in protein metabolism
29. Relapse of depression after rapid depletion of tryptophan
30. Clinical and physiological consequences of rapid tryptophan depletion
31. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients
32. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory
33. Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion
34. Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy
35. The biology of impulsivity and suicidality
36. Cytokines and anorexia: A brief overview
37. Cytokine-associated emotional and cognitive disturbances in humans
38. Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid
39. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation?
40. Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2, 3-dioxygenase in brain of C57BL6 mice
41. IFN-gamma activated indoleamine 2, 3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism
42. Biologic-response-modifier-induced indoleamine 2, 3-dioxygenase activity in human peripheral blood mononuclear cell cultures
43. Treatment with interferon-alpha (IFNalpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNalpha-induced depressive and anxiety symptoms and immune activation
44. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection
45. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms
46. Paroxetine for the prevention of depression induced by high-dose interferon alfa